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ABSTRACT
Introduction: The use of risk scores for the assessment of major bleeding and 
stroke in patients with atrial fibrillation (AF) helps evaluate the risks and benefits of 
oral anticoagulation therapy. The aim of this study was to describe the percentage of 
patients receiving anticoagulants for non-valvular AF with a high risk of major bleeding 
based on the HAS-BLED score, as well as identify potential modifiable risk factors of 
bleeding and compare the risk of major bleeding with the risk of stroke.
Methods: Retrospective cohort study involving patients of the anticoagulation 
outpatient clinic of the Division of Internal Medicine at Hospital de Clínicas de Porto 
Alegre. Major bleeding risk was estimated based on the HAS-BLED score and stroke 
risk was determined using the CHADS2 and CHA2DS2-VASc scores.
Results: Sixty-three patients were investigated (mean age 74.3±10.9 years). 
The median HAS-BLED score was 2 points, 19 (30.2%) patients had a score ≥ 3 
(high risk). The most prevalent modifiable risk factors were labile TP/INR (36.5%) and 
concomitant use of drugs (30.2%). The absolute risk of major bleeding based on the 
HAS-BLED score was higher than the risk of stroke in three (4.8%) and four (6.3%) 
patients in comparison with the CHADS2 and CHA2DS2-VASc score, respectively.
Conclusions: We concluded that the percentage of patients with high risk of major 
bleeding is similar to the rate found in the national literature (30.2%). In addition, the 
most prevalent modifiable risk factors in our cohort were labile TP/INR and concomitant 
drug use.
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Oral anticoagulant (OAC) therapy with vitamin K antagonists (VKAs) has 
been used for more than 50 years. There is solid evidence on its efficacy 
in preventing thromboembolic complications in different clinical settings, 
including patients with atrial fibrillation (AF)1. Nevertheless, the benefit of 
anticoagulation must be balanced against the risk of increased hemorrhage1.
Strategies of treatment individualization based on a trade-off between the 
treatment-related individual benefit and harm are facilitated by the availability 
of clinical tools to predict patients’ risk. The CHADS2 and CHA2DS2-VASc 
scores are used to evaluate OAC therapy and identify those patients who 
will benefit from this intervention. These scores are clinical risk factor-based 
schemes to predict the risk of stroke in patients with AF2. In addition, the 
HAS-BLED score predicts the risk of bleeding, which is the major harm 
caused by OAC therapy3. Patients with a HAS-BLED score ≥ 3 are at high 
risk of bleeding. Therefore, these patients should be treated with caution, 
being closely followed up4.
Bleeding events may have significant prognostic and management 
implications. These events may lead to discontinuation of treatment, long-term 
disability, or even death. The fear of hemorrhagic complications is one of the 
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main reasons why physicians may withhold OAC 
therapy in some patients1.
The aim of this study was to describe the percentage 
of patients receiving anticoagulants for non-valvular 
AF with a high risk of major bleeding based on 
the HAS-BLED score, as well as identify potential 
modifiable risk factors of bleeding and compare the 
risk of major bleeding with the risk of stroke.
METHODS
A retrospective cohort study was conducted including 
all patients with non-valvular AF on OAC with VKAs 
attending the anticoagulation outpatient clinic of the 
Division of Internal Medicine at the Hospital de Clínicas 
de Porto Alegre (HCPA). All patients who were seen 
at the clinic during three consecutive months (October 
to December 2010) were screened for inclusion in the 
study. We believe that the duration of the screening 
period was adequate because the patients attended 
the outpatient clinic for at most two months. Patients 
with valvular AF, i.e., with mitral stenosis or previous 
heart valve surgery, were excluded because the 
ischemic stroke predictive scores (CHADS2 and 
CHA2DS2-VASc) do not include this disorders
5,6. 
The patients who were lost to follow-up, died, or 
whose anticoagulation therapy was discontinued 
were included in our analysis.
We performed a retrospective review of outpatient 
visits, emergency visits, and hospitalizations from 
January to December 2011 based on the patients’ 
electronic medical records. We assessed age, sex, 
left ventricular ejection fraction (LVEF), complex 
aortic plaque and history of transient ischemic attack 
(TIA), stroke, diabetes, peripheral artery disease, 
hypertension, myocardial infarction, and heart 
failure. Previous systemic embolism, combined use 
of antiplatelet agents, oral anticoagulant (warfarin 
or phenprocoumon), and number of prothrombin 
time/international normalized ratio (PT/INR) tests 
were also investigated. Patients were evaluated in 
terms of anticoagulation control (using PT/INR tests) 
and occurrence of adverse events (ischemic stroke, 
systemic embolism, or bleeding).
Major bleeding was defined as any bleeding 
requiring hospitalization and/or causing a decrease in 
hemoglobin level of more than 2 g/dL and/or requiring 
blood transfusion7. Presence of chronic dialysis or 
renal transplantation or serum creatinine ≥ 200 μmol/L 
(2.26 mg/dL) was classified as abnormal kidney 
function7. Abnormal liver function was defined as 
chronic hepatic disease (e.g., cirrhosis) or biochemical 
evidence of significant hepatic derangement (e.g., 
bilirubin > 2x upper limit of normal, in association with 
AST/ALT/ALP > 3x upper limit of normal)7. Anemia 
was defined if hemoglobin was below 13.0 g/L in 
men and 12.0 g/L in women8. Time in therapeutic 
range was calculated based on the percentage of 
PT/INR tests in a 2.0-3.0 range and the Rosendaal 
linear interpolation method9 using the INR-Day 0.2.1 
software.
Major bleeding risk was calculated using the 
HAS-BLED score, an acronym for hypertension 
(uncontrolled, >160 mmHg systolic), abnormal 
renal/liver function (1 point for presence of renal 
or liver impairment, maximum 2 points), stroke 
(previous history, particularly lacunar), bleeding history 
(major) or predisposition (anemia), labile INR (time 
in therapeutic range < 60%), elderly (> 65 years), 
drugs/alcohol concomitantly (antiplatelet agents, 
nonsteroidal anti-inflammatory drugs; 1 point for 
drugs plus 1 point for alcohol excess, maximum 
2 points)7. Patients were classified as low risk if their 
score was 0; intermediate risk for score 1-2, and high 
risk for patients with score ≥ 3.
The mean risk of ischemic stroke was calculated 
based on the risk factors included in the CHADS2 and 
CHA2DS2-VASc scores (low risk = 0; intermediate risk = 1; 
high risk =≥ 2). The CHADS2 score was calculated 
based on presence of cardiac failure, hypertension, 
age above 75 years, diabetes, and prior stroke or TIA 
as previously described5. The CHA2DS2-VASc score 
included age 65-74, female gender, vascular disease, 
and age 75 or older, and overweight, with 2 points6. 
Transthoracic echocardiogram was used to estimate 
LVEF using the Simpson method in the presence of 
segmental changes or the Teichholz method in the 
absence of segmental changes. PT for determination 
of INR was performed at the Hematology Laboratory 
of the HCPA using a standard coagulation testing 
system (Siemens BCS).
Assuming a 95% confidence level and a margin 
of error of 3.5, a sample size of 47 patients was 
calculated to estimate the outcome major bleeding 
(annual incidence of 1.5%)7. Our analysis was carried 
out in WinPepi, version 11.32. Descriptive data were 
reported as number (%), mean ± standard deviation 
(SD), and median. We used SPSS 15.0 for statistical 
analysis. The present study is a subanalysis of a 
previous study10 submitted and approved by the 
Research Ethics Committee at the HCPA.
RESULTS
During the study period, 137 patients were seen 
at the anticoagulation outpatient clinic. Of these, 
63 (46.0%) were receiving OAC therapy for non-valvular 
AF and were included in the study. During the follow-up 
period, eight patients did not complete the 1-year 
follow-up: five discontinued the use of OAC (7.9%), 
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two were lost to follow-up (3.2%), and one died (1.6%) 
of a cause unrelated to anticoagulation. Thus, of the 
63 patients included in the study, 55 completed the 
365-day follow-up period, and the other eight patients 
had a mean follow-up of 128.5 days. The demographic 
characteristics of the sample are shown in Table 1. 
The presence of complex aortic plaques was not 
included in Table 1 because only four patients 
(6.3%) underwent transesophageal echocardiogram. 
In terms of risk of stroke, we found that our patients 
had a high risk for this outcome. Since patients 
with a score ≥ 2 are considered high-risk patients, 
with an indication for anticoagulation according to 
the CHADS2 and CHA2DS2-VASc scores, 95.2 and 
100% of our patients, respectively, were included in 
this risk category.
The 63 patients included in the present study 
underwent 738 PT/INR tests (mean 11.7±5.1 
tests/patient). Of these, 395 tests (53.5%) showed 
PT/INR between 2.0 and 3.0. As to time in therapeutic 
range analyzed by the Rosendaal linear interpolation 
method, in 64.8% of the follow-up period, PT/INR 
remained between 2.0 and 2.9; and in 89.9% of the 
follow-up period, PT/INR was between 1.5 and 3.4.
The absolute risk of major bleeding based on 
the HAS-BLED score was classified as high risk in 
30.2% of patients (table 2). Elderly was the most 
prevalent HAS-BLED component. In terms of other 
major bleeding risk factors, 21 (33.3%) patients 
had predisposing factor (anemia), 19 (30.2%) used 
concomitant drugs (acetylsalicylic acid was the only 
antiplatelet agent associated), no patients used 
chronically nonsteroidal anti-inflammatory drugs, two 
(3.2%) patients had history of major bleeding, and 
one (1.6%) patient was alcoholic. The most prevalent 
modifiable risk factors were labile TP/INR (36.5%) 
and concomitant use of drugs (30.2%); uncontrolled 
hypertension was detected only in 4.8% (figure 1). 
During the follow-up period, three (4.8%) patients 
had a major bleeding event, all of them belonged to 
the high-risk group.
The absolute risk of major bleeding based on the 
HAS-BLED score was higher than the stroke risk in 
three (4.8%) and four (6.3%) patients in comparison 
with the CHADS2 and CHA2DS2-VASc score, 
respectively. A complete concordance between the risk 
categories was found in 33.3% (CHADS2/HAS-BLED) 
and 30.1% (CHA2DS2-VASc/HAS-BLED) of patients 
(tables 3 and 4).
Table 1: Demographic characteristics of the sample.
Characteristics n = 63
Age, mean (± SD) 74.3 ± 10.9
Age ≥ 75 years, n (%) 39 (61.9)
Female, n (%) 31 (49.2)
CHADS2, median (IQR) 3 (3-4)
CHA2DS2-VASc, median (IQR) 5 (4-6)
HAS-BLED, median (IQR) 2 (1-3)
Use of warfarin, n (%) 62 (98.4)
Hypertension, n (%) 62 (98.4)
Heart failure, n (%) 42 (66.7)
% LVEF, mean (± SD) 56.1 ± 12.3
LVEF < 40%, n (%) 7 (11.1)
Diabetes, n (%) 32 (50.8)
Previous stroke, n (%) 20 (31.7)
Associated use of ASA, n (%) 19 (30.2)
Previous MI, n (%) 10 (15.9)
Peripheral arterial disease, n (%) 10 (15.9)
Previous systemic embolism, n (%) 4 (6.3)
Previous TIA, n (%) 1 (1.6)
SD: standard-deviation, IQR= Interquartile Range, LVEF: left ventricular 
ejection fraction, ASA: acetylsalicylic acid, MI: myocardial infarction, 
TIA: transient ischemic attack.
Table 2: Major bleeding risk on the HAS-BLED score.
HAS-BLED 
score
n (%) Major bleeding risk, n (%)
0 4 (6.4) Low, 4 (6.3)
1 12 (19.0) Intermediate, 40 (63.5)
2 28 (44.4) High, 19 (30.2)
3 10 (15.9)
4 5 (7.9)
5 4 (6.4)
Figure 1: Prevalence of components of the HAS-BLED score.
Table 3: CHADS2 and HAS-BLED co-distribution according 
to the score-based risk categories.
HAS-BLED risk category
CHADS2 risk 
category
Low Intermediate High n (%)
Low 0 0 0 0 (0)
Intermediate 1 2 0 3 (4.8)
High 3 38 19 60 (95.2)
n (%) 4 (6.3) 40 (63.5%) 19 (30.2) 63
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DISCUSSION
The percentage of patients with high risk of major 
bleeding in the present study was 30.2%. We found 
that labile TP/INR and concomitant drug use were the 
most prevalent modifiable risk factors. In addition, we 
found that the risk of major bleeding was higher than 
the risk of stroke in just 6.3% of patients. Because 
there are not national records of AF in Brazil, the 
rate of major bleeding risk we found was compared 
with similar values from other countries.
In a survey conducted in Denmark11 involving 
44,771 non-valvular AF patients receiving OAC, 14,268 
(31.9%) were considered to have high bleeding risk, 
whereas in a Swedish nationwide cohort study12 of 
170,291 non-valvular AF patients, 64,288 (37.8%) 
were categorized as “high bleeding risk” based on 
the HAS-BLED score.
AF is usually asymptomatic and its first manifestation 
may be a devastating stroke. Individual assessment 
of risk of stroke and bleeding should be performed in 
patients who are candidates to receive OAC therapy 
so that appropriate stroke prevention can be offered. 
These risks should be discussed with the patient. 
The use of risk scores (such as the CHA2DS2-VASc 
and HAS-BLED) may help to inform the patient about 
the treatment strategy4.
Regarding bleeding risk, the availability of tools 
has helped clinicians to decide about the appropriate 
treatment, making it possible to assess the risks 
and benefits of the therapy. However, it is important 
to note that these bleeding risk tools should not be 
used to identify patients whose treatment needs to 
be discontinued. Conversely, these tools should 
be used to measure the patients’ bleeding risk and 
determine appropriate risk reduction measures, i.e. 
treating modifiable risk factors (e.g.: anemia, drug 
use, alcohol use, uncontrolled hypertension, labile 
INRs) and providing support services to ensure close 
monitoring and regular review13. Thus, bleeding 
risk assessment with the HAS-BLED score should 
not be used as a justification not to prescribe OAC 
but rather to identify those patients who need more 
intense monitoring and education interventions4.
Because these thrombotic and bleeding risk scores 
share some risk factors, they are not expected to 
be independent. Nevertheless, the degree of their 
association has never been clearly determined 
until a recent study was conducted. In the study 
by Marcucci et al. with 3,920 patients, the authors 
found a correlation of 0.416 between the HAS-BLED 
and CHADS2 scores and a correlation of 0.512 
between the HAS-BLED and CHA2DS2-VASc scores. 
The bleeding risk was equal to or lower than the 
cardioembolic risk in 89% (CHADS2/HAS-BLED) 
and 97% (CHA2DS2-VASc/HAS-BLED) of patients. 
Full agreement between the risk categories 
was found in 39.6% (CHADS2/HAS-BLED) and 
21.7% (CHA2DS2-VASc/HAS-BLED) of patients. 
Conversely, 4.4% (CHADS2/HAS-BLED) and 7.7% 
(CHA2DS2-VASc/HAS-BLED) of patients had high 
cardioembolic risk/low bleeding risk or vice versa. There 
was a trend of increased frequency of stroke when 
there was increased bleeding risk within cardioembolic 
risk categories and vice versa. This finding showed 
that cardioembolic and bleeding risk classifications 
are correlated but not exchangeable. Therefore, 
a combined risk assessment is recommended 
instead of a strategy based only on cardioembolic 
risk evaluation2.
There are some limitations in our study. First, the 
retrospective design may have influenced the quality 
and consistency of the data collected. Besides, 
the patients’ medical records included only events 
(cardiovascular and bleeding) that occurred at the 
HCPA or that were reported by the patients during 
clinical care. Second, the relative small sample size 
associated with the short follow-up period may have 
underestimated the occurrence of adverse events, 
especially events related to AF, which have a longer 
latency period. Third, none of the patients had abnormal 
renal/liver function, which affects major bleeding risk. 
Finally, the fact that the study was conducted at a 
single center may also be considered a limitation.
In conclusion, according to the HAS-BLED score, 
most patients using OAC for AF had intermediate or 
high risk of bleeding. Although the risk of bleeding 
should not exclude patients from OAC therapy, it 
may help to identify those patients who have to be 
more carefully managed and/or reviewed, in addition 
to highlighting the common correctable bleeding risk 
factors that may be addressed. Even in those patients 
with high bleeding risk, it is beneficial to provide 
them with OAC therapy because of their increased 
risk of stroke/thromboembolism14. The percentage 
of non-valvular AF patients categorized as “high 
bleeding risk” by the HAS-BLED score in our study 
was similar to the rates found in the literature.
Table 4: CHA2DS2-VASc and HAS-BLED co-distribution 
according to the score-based risk categories.
HAS-BLED Risk Category
CHA2DS2-VASc 
risk category
Low Intermediate High n (%)
Low 0 0 0 0 (0)
Intermediate 0 0 0 0 (0)
High 4 40 19 63 (100)
n (%) 4 (6.3) 40 (63.5) 19 (30.2) 63
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